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Abstract
Thyroid disease is a common problem among women of reproductive age but often goes 
undiagnosed. Maternal thyroid disease has been associated with increased risk of craniosynostosis. 
We hypothesized that known risk factors for thyroid disease would be associated with risk of 
craniosynostosis among women not diagnosed with thyroid disease. Analyses included mothers of 
1,067 cases and 8,494 population-based controls who were interviewed for the National Birth 
Defects Prevention Study. We used multivariable logistic regression to estimate adjusted odds 
ratios (AOR) and 95% confidence intervals (CI). After excluding women with diagnosed thyroid 
disease, younger maternal age (AOR 0.7, 95% CI 0.6–0.9, for <25 years versus 25–29), black or 
other race-ethnicity (AOR 0.3, 95% CI 0.2–0.4 and AOR 0.6, 95% CI 0.4–0.8, respectively, 
relative to non-Hispanic whites), fertility medications or procedures (AOR 1.5, 95% CI 1.2–2.0), 
and alcohol consumption (AOR 0.8, 95% CI 0.7–0.9) were associated with risk of 
craniosynostosis, based on confidence intervals that excluded 1.0. These associations with 
craniosynostosis are consistent with the direction of their association with thyroid dysfunction 
(i.e., younger age, black race-ethnicity and alcohol consumption are associated with reduced risk 
and fertility problems are associated with increased risk of thyroid disease). This study thus 
provides support for the hypothesis that risk factors associated with thyroid dysfunction are also 
associated with risk of craniosynostosis. Improved understanding of the potential association 
between maternal thyroid function and craniosynostosis among offspring is important given that 
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craniosynostosis carries significant morbidity and that thyroid disease is under-diagnosed and 
potentially modifiable.
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INTRODUCTION
Thyroid disease is a common condition among women of reproductive age. Hypothyroidism 
affects 2–5% of pregnant women, whereas current or past hyperthyroidism (primarily 
Graves’ disease) affects about 1% [Laurberg et al., 1998; Casey et al., 2006]. Presence of 
anti-thyroid antibodies is much more common, observed in 13% of pregnant women without 
recognized thyroid disease in a large US study [Haddow et al., 2010]. Even in the absence of 
overt thyroid disease, these antibodies are associated with higher levels of thyroid 
stimulating hormone (TSH) and are predictive of the development of overt thyroid disease. 
In addition, transient hyperthyroidism (thyrotoxicosis) affects up to 3% of women during 
early pregnancy, due to the TSH-like activity of placental hCG (human chorionic 
gonadotropin) [Glinoer, 1998]. Hypo- and hyperthyroidism, as well as the presence of anti-
thyroid antibodies in the absence of thyroid disease, are associated with increased risk of 
adverse pregnancy outcomes such as spontaneous abortion and preterm delivery [van den 
Boogaard et al., 2011; He et al., 2012; Mannisto et al., 2013]. Improved understanding of the 
association of maternal thyroid function with reproductive outcomes is particularly 
important given that thyroid disease often goes undiagnosed [Hollowell et al., 2002], and the 
appropriate approach to screening and management of thyroid disease during pregnancy is a 
topic of ongoing debate [Stagnaro-Green and Pearce, 2012].
Craniosynostosis (CS), the premature fusion of one or more cranial sutures, leads to 
abnormal craniofacial form and function. It may be associated with increased intracranial 
pressure leading to abnormal neurocognitive development, and most affected infants require 
extensive reconstructive surgery [Speltz et al., 2004; Rasmussen et al., 2008; Starr et al., 
2012]. Wehypothesize that maternal thyroid hormones or anti-thyroid antibodies may result 
in exposure of fetal tissues to excessive amounts of thyroid hormone, which in turn may 
cause premature suture fusion. A variety of case-only studies suggest that thyroid hormones 
may be associated with craniosynostosis [Penfold and Simpson, 1975; Johnsonbaugh et al., 
1978; Daneman and Howard, 1980; Cove and Johnston, 1985; Leonard et al., 1987; 
Stevenson and Trent, 1990; Nishihara et al., 2006].More recently, Rasmussen et al. reported 
an association of thyroid disease with risk of craniosynostosis using data from the National 
Birth Defects Prevention Study [Rasmussen et al., 2007]. One explanation for these findings 
is that thyroid hormones stimulate osteogenesis. In particular, treatment with thyroid 
hormones has been shown to stimulate osteogenesis of the skull and premature narrowing of 
cranial sutures in experimental studies [Akita et al., 1994].
Many risk factors for thyroid disease have been identified, such as older maternal age, white 
or Hispanic race-ethnicity, and higher body mass index [Hollowell et al., 2002; Knudsen et 
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al., 2005]. In this study, we examined whether risk factors for thyroid disease, among 
mothers who did not report having thyroid disease, were associated with increased risk of 
craniosynostosis.
METHODS
Study Design and Data Collection
This study included data on deliveries that occurred from 1997 to 2007 and were part of the 
NBDPS, a case-control study of birth defects that was conducted in ten states of the U.S. 
Details about study design and methods have been published [Cogswell et al., 2009; Yoon et 
al., 2001]. Most study sites included liveborn infants, fetal deaths (at greater than 20 weeks 
gestation), and electively terminated cases. Each site selected a population-based set of 
nonmalformed, liveborn control infants during each study year from birth certificates or 
birth hospitals.
Information on case infants was obtained from hospital reports and medical records 
[Rasmussen et al., 2003], and one clinical geneticist (SAR) provided a final review of all 
cases to ensure that they all met standard eligibility criteria. All craniosynostosis cases were 
verified by radiographic imaging (e.g., skull radiograph or head CT) or surgery. Infants with 
recognized or strongly suspected single-gene disorders or chromosomal abnormalities were 
ineligible. The specific suture(s) involved was also identified (i.e., sagittal, coronal, metopic, 
lambdoid, multiple, or unknown). Infants with more than one type of involved suture (e.g., 
sagittal and coronal sutures both prematurely closed) were counted only in the multiple 
suture category.
Maternal interviews were conducted using a standardized, computer-based questionnaire by 
telephone, in English or Spanish. Interviews were conducted with 71% of eligible case 
mothers and 66% of eligible control mothers. The median time from delivery to interview 
was 14 months for cases and 8 months for controls.
Study Variables
Maternal thyroid disease was based on a mother’s report of a thyroid disorder or taking 
thyroid medication at any time during pregnancy [Rasmussen et al., 2007]. This information 
was in response to general questions about medical conditions; questions specifically about 
thyroid disease were not asked. We examined the association of craniosynostosis with the 
following factors related to maternal thyroid dysfunction: maternal age, race-ethnicity, 
parity, pre-pregnancy body mass index (BMI), fertility medications or procedures (as a 
proxy for fertility problems), previous miscarriages, diabetes, hypertension, intake of anti-
depressants (a proxy for depression) or iron-only supplements (a proxy for anemia), 
smoking, and alcohol consumption [Glinoer 1998; Hollowell et al., 2002; Belin et al., 2004; 
Knudsen et al., 2005; Zimmermann et al., 2007; Ashoor et al., 2010; Carle et al., 2012a; 
Carle et al., 2012b; De Groot et al., 2012; Wu et al., 2013].
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First, we examined the association of maternal thyroid disease with craniosynostosis, given 
that our previous analysis of this study question only included data on births through 2002 
[Rasmussen et al., 2007]. The current analysis was adjusted only for maternal age, as was 
done for the previous study. We used logistic regression to estimate odds ratios (OR) and 95 
percent confidence intervals (CI). Second, we examined the association of each covariate 
with maternal report of thyroid disease among the controls, using Chi-square tests. Third, we 
conducted logistic regression models that included all covariates but that excluded women 
who reported thyroid disease, to determine the independent association of each covariate 
with craniosynostosis. We examined associations with craniosynostosis overall and with 
each suture type separately.
RESULTS
There were 1,067 cases and 8,494 controls available for analysis. The sagittal suture was 
affected in 566 (53%) cases, the metopic suture in 194 (18%), the coronal suture in 187 
(18%), the lambdoid suture in 32 (3%), multiple sutures in 85 (8%), and unspecified in three 
(0.3%). A total of 37 case mothers (3.5%) and 191 control mothers (2.3%) reported thyroid 
disease. Most women with thyroid disease did not specify the type of thyroid disease (81% 
of affected case mothers, 87% of affected control mothers), and many women with thyroid 
disease did not report intake of a specific thyroid-related medication (19% of cases, 35% of 
controls). Among those that did report taking a medication, most reported taking 
levothyroxine (93% of cases, 94% of controls). The adjusted OR for craniosynostosis and 
maternal thyroid disease was 1.4 (95% CI 0.9, 1.9). ORs were similar for specific affected 
sutures, with the exception of multiple affected sutures, for which the OR was 3.0 (95% CI 
1.3, 6.9) (Table I).
Relative to control mothers who did not report thyroid disease, control mothers who did 
report thyroid disease were more likely to be older, be non-Hispanic white, report fertility 
medications or procedures, have had a previous miscarriage, have gestational diabetes, and 
take anti-depressants or iron-only supplements, and less likely to smoke, based on P<0.05 
(Table II). Parity, BMI, hypertension and alcohol consumption were not statistically 
different (P≥0.05).
We then examined the association of the studied risk factors with craniosynostosis after 
adjustment for all other factors and excluding women who reported thyroid disease. 
Maternal younger age (OR 0.7,95% CI 0.6–0.8, for <25 years vs. 25–29), black (OR 0.3, 
95% CI 0.2–0.4) or other race-ethnicity (OR 0.6, 95% CI 0.4–0.8), fertility medications or 
procedures (OR 1.5, 95% CI 1.2–2.0), and alcohol consumption (OR 0.8, 95% CI 0.7–0.9) 
were associated with risk of craniosynostosis, based on confidence intervals that excluded 
1.0 (Table III). Many results were similar regardless of suture type but a few differences 
from all cases grouped together are noteworthy: sagittal synostosis had the weakest 
association with fertility treatments; risk of coronal synostosis was not reduced among 
infants born to mothers with Hispanic and other race-ethnicity; and risk of coronal 
synostosis was elevated among infants born to mothers with pre-gestational diabetes. 
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Several results were different for lambdoid cases but should be interpreted with caution 
given that analyses of this group included only 31 cases (Table III).
DISCUSSION
We examined the association of craniosynostosis with several maternal characteristics that 
are related to increased risk of thyroid disease, among women who did not report having 
thyroid disease. After adjustment for all other studied factors, reduced risk of 
craniosynostosis was observed among babies born to women who were younger, had black 
or other race-ethnicity, and consumed alcohol, and increased risk was observed among 
women who took fertility medications or had fertility-related procedures. The directions of 
the associations of these risk factors with craniosynostosis are consistent with the directions 
of their associations with thyroid dysfunction. The findings thus lend support to a potential 
association of craniosynostosis with thyroid dysfunction, even among women who have not 
been diagnosed with overt thyroid disease.
The associations of craniosynostosis with many of the studied risk factors have been studied 
previously [Reefhuis et al., 2003; Carmichael et al., 2008; Boulet et al., 2010; Sanchez-Lara 
et al., 2010; Richardson et al., 2011]. The novelty of the current study is that they have been 
examined simultaneously in the context of a unifying hypothesis regarding thyroid disease, 
and they have all been adjusted for confounding by each other. Previous studies have 
typically focused on one or a few risk factors at a time, adjusted for fewer covariates, 
included fewer cases, and did not exclude women diagnosed with overt thyroid disease.
Ideally, we would like to examine directly whether maternal thyroid hormone levels or the 
presence of anti-thyroid antibodies are associated with craniosynostosis. Given that such 
measurements were not available and would be very difficult to obtain prospectively given 
the rarity of craniosynostosis, we took the alternative approach of studying risk factors for 
thyroid dysfunction. This is akin to an approach that has been used to understand the 
association of estrogen-related exposures with hypospadias and testicular cancer 
[Carmichael et al., 2007; English et al., 2003]. Initial analyses confirmed that most of the 
studied maternal characteristics were indeed associated with reported thyroid disease among 
control mothers. This lends internal validity to our approach.
In our previous analysis of the association of maternal self-reported thyroid disease with 
craniosynostosis, which was based on births from 1997–2002, the OR was 2.3 (95% CI 1.4, 
4.0). In that study, 4.4% of case mothers (19/431) and 1.6% of control mothers (65/4,094) 
reported having thyroid disease. In the current study, which includes births from 1997–2007, 
the respective OR and percentages are 1.4 (95% CI 0.9, 1.9), 3.5% and 2.3% of controls. We 
do not have an explanation for the difference in results using more recent data. Many case 
reports and series that involve varied scenarios of maternal or newborn thyroid dysfunction 
have suggested an association with craniosynostosis [Penfold and Simpson, 1975; 
Johnsonbaugh et al., 1978; Daneman and Howard, 1980; Cove and Johnston, 1985; Leonard 
et al., 1987; Stevenson and Trent, 1990; Nishihara et al., 2006]. The osteogenic effects of 
thyroid hormone and experimental data also support the hypothesis [Akita et al., 1994]. 
Supportive observational epidemiologic data are limited, with the NBDPS offering the 
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largest set of detailed observational data to date that can be used to address this question. 
Several other epidemiologic studies have examined the association of maternal thyroid 
disease with birth defects, but sample sizes have been quite limited [Momotani et al., 1984; 
Khoury et al., 1989; Wing et al., 1994; Chen et al., 2011; Yoshihara et al., 2012; Andersen et 
al., 2013; Kallen and Norstedt Wikner, 2014]. A large study of Texas births reported lower 
thyroxine levels in newborn screening bloodspots among infants with craniosynostosis 
[Hashmi et al., 2012], a finding that could be expected if the mothers were hyperthyroid 
during pregnancy.
We acknowledge that thyroid dysfunction and its association with the studied risk factors are 
complex. For example, alcohol consumption has recently been shown to be protective 
against development of autoimmune hypo- or hyperthyroidism [Carle et al., 2012b], which 
supports our observation of reduced risk among women who drank. Another example is 
smoking. Some studies have suggested that smoking is associated with increased risk of 
craniosynostosis [Kallen, 1999; Honein and Rasmussen, 2000; Carmichael et al., 2008]. 
However, a recent report suggested that smoking cessation was associated with increased 
incidence of hypothyroidism [Carle et al., 2012a]. We would certainly not advocate alcohol 
consumption or smoking during pregnancy, but this information is potentially useful from an 
etiologic standpoint and from the perspective of trying to synthesize varied findings. We 
would also like to note that although the findings do lend support to our hypothesis, 
mechanisms other than undiagnosed thyroid dysfunction could also explain the observed 
associations.
Strengths of the current study include its population-based, multi-center design, careful case 
ascertainment, large size, suture-specific analyses, and simultaneous examination of 
multiple risk factors. Interviews were conducted with mothers of 71% of eligible cases and 
66% of controls. We have no reason to believe that participation was differentially related to 
the studied risk factors for cases versus controls, but if it was, then selection bias may have 
affected our results. Similarly, we do not know whether mothers’ recall of any risk factors 
was related to case or control status, but if it was, then recall bias could have affected our 
results.
This study’s findings provide support for the hypothesis that risk factors associated with 
thyroid dysfunction are also associated with risk of craniosynostosis. Improving our 
understanding of the potential association between maternal thyroid function and 
craniosynostosis among offspring is important, given that thyroid disease is common, under-
diagnosed and potentially modifiable.
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TABLE I
Association of Maternal Thyroid Disease With Craniosynostosis, National Birth Defects Prevention Study, 
1997–2007
Affected suture(s) No. cases with and without thyroid disease* AOR (95% CI), adjusted for maternal age**
Any 37/1030 1.4 (0.9, 1.9)
Sagittal 19/547 1.3 (0.8, 2.1)
Metopic 6/188 1.3 (0.6, 3.0)
Coronal 6/181 1.2 (0.5, 2.9)
Lambdoidal 0/32 —
Multiple 6/79 3.0 (1.3, 6.9)
*
The sum of the two numbers in the column equals the total number of cases; eg, 37 + 1030 = 1067 cases with any affected suture. Number of 
controls with and without thyroid disease was 191 and 8303, respectively.
**
Adjusted for maternal age as <25, 25–29, 30–34, 35+ years.
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TABLE II
Association of Maternal Characteristics With Thyroid Disease Among Control Mothers
Percent, among mothers with
thyroid disease (n = 191)*
Percent, among mothers without
thyroid disease (n = 8,303)* P-value
Age (years) <0.001
   <25 11 34
   25–29 29 27
   30–34 34 25
   35 or older 27 14
Race-ethnicity <0.001
   Non-Hispanic white 73 58
   Non-Hispanic black 4 11
   Hispanic 14 23
   Other 8 8
Parity (previous live births)
   0 33 40 0.132
   1 37 33
   2 or more 30 27
Pre-pregnancy body mass index**
   Underweight (<18.5 kg/m2) 3 5 0.066
   Normal weight (18.5–24.9 kg/m2) 49 53
   Overweight (25.0–29.9 kg/m2) 25 22
   Obesity (30–39.9 kg/m2) 20 14
   Extreme obesity (40 or more kg/m2) 3 2
Fertility medications or procedures 12 4 <0.001
Previous miscarriage
   None 68 78 0.005
   1 25 16
   2 or more 7 6
Diabetes
   None 87 93 0.037
   Pre-gestational 1 1
   Gestational 11 6
Hypertension before or during pregnancy 12 13 0.689
Took anti-depressants (from 3 months
  before or during pregnancy)
7 4 0.047
Took iron-only supplement
   None 77 72 0.029
   Began in 1st trimester 7 13
   Began in 2nd trimester 9 11
   Began in 3rd trimester 6 4
Smoked (1st trimester) 9 16 0.016
Alcohol consumption (1st trimester) 25 22 0.245
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*
Column percents do not add to 100% due to missing data.
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